Aging of the Brain and Alzheimer's Disease

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Alzheimer's disease (AD) is the most common progressive dementia syndrome of the elderly. Because of prevalence, lack of mechanism-based treatments, care costs, and impact on individuals and families, AD is an extraordinarily challenging disease. It is characterized by dysfunction and death of specific populations of neurons, particularly those in neural systems involved in memory and cognition, and by intracellular and extracellular protein aggregates (tau and A. Α peptides) in neurofibrillary tangles (NFTs) and amyloid plaques, respectively. Genetic evidence indicates that the inheritance of mutations in several genes causes autosomal dominant familial AD (fAD) and the majority of mutations increase the levels of toxic A. Α amyloid peptide species in the brain. In this review, we describe the clinical features, diagnostic studies, the neuropathology, and the biochemistry of the disease with a particular focus on the amyloid precursor protein and Α- and Α-secretase enzyme activities which generate the A. Α peptide. Taking advantage of this new information, and the ability to manipulate genes, it is has been possible to produce transgenic models of the disease and to target genes encoding proteins critical in the disease pathways. In turn, this information has been used to develop experimental therapeutics, including strategies to reduce secretase activities and to clear the amyloid peptide from the brain. These discoveries offer genuine hope for the development of mechanism-based therapeutics for this illness.

Original languageEnglish (US)
Title of host publicationEncyclopedia of Neuroscience
PublisherElsevier Ltd
Pages187-195
Number of pages9
ISBN (Print)9780080450469
DOIs
StatePublished - 2010

Fingerprint

Brain Diseases
Alzheimer Disease
Amyloid Precursor Protein Secretases
Peptides
Amyloid
Hope
Mutation
Neurofibrillary Tangles
Aptitude
Poisons
Amyloid Plaques
Staphylococcal Protein A
Brain
Health Care Costs
Biochemistry
Cognition
Genes
Dementia
Neurons
Enzymes

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Aging of the Brain and Alzheimer's Disease. / Price, D. L.; Savonenko, Alena; Albert, Marilyn; Troncoso, Juan C; Wong, Philip Chun.

Encyclopedia of Neuroscience. Elsevier Ltd, 2010. p. 187-195.

Research output: Chapter in Book/Report/Conference proceedingChapter

Price, D. L. ; Savonenko, Alena ; Albert, Marilyn ; Troncoso, Juan C ; Wong, Philip Chun. / Aging of the Brain and Alzheimer's Disease. Encyclopedia of Neuroscience. Elsevier Ltd, 2010. pp. 187-195
@inbook{93e6cb62ef104b04a49c350c6794d6c1,
title = "Aging of the Brain and Alzheimer's Disease",
abstract = "Alzheimer's disease (AD) is the most common progressive dementia syndrome of the elderly. Because of prevalence, lack of mechanism-based treatments, care costs, and impact on individuals and families, AD is an extraordinarily challenging disease. It is characterized by dysfunction and death of specific populations of neurons, particularly those in neural systems involved in memory and cognition, and by intracellular and extracellular protein aggregates (tau and A. Α peptides) in neurofibrillary tangles (NFTs) and amyloid plaques, respectively. Genetic evidence indicates that the inheritance of mutations in several genes causes autosomal dominant familial AD (fAD) and the majority of mutations increase the levels of toxic A. Α amyloid peptide species in the brain. In this review, we describe the clinical features, diagnostic studies, the neuropathology, and the biochemistry of the disease with a particular focus on the amyloid precursor protein and Α- and Α-secretase enzyme activities which generate the A. Α peptide. Taking advantage of this new information, and the ability to manipulate genes, it is has been possible to produce transgenic models of the disease and to target genes encoding proteins critical in the disease pathways. In turn, this information has been used to develop experimental therapeutics, including strategies to reduce secretase activities and to clear the amyloid peptide from the brain. These discoveries offer genuine hope for the development of mechanism-based therapeutics for this illness.",
author = "Price, {D. L.} and Alena Savonenko and Marilyn Albert and Troncoso, {Juan C} and Wong, {Philip Chun}",
year = "2010",
doi = "10.1016/B978-008045046-9.00539-8",
language = "English (US)",
isbn = "9780080450469",
pages = "187--195",
booktitle = "Encyclopedia of Neuroscience",
publisher = "Elsevier Ltd",

}

TY - CHAP

T1 - Aging of the Brain and Alzheimer's Disease

AU - Price, D. L.

AU - Savonenko, Alena

AU - Albert, Marilyn

AU - Troncoso, Juan C

AU - Wong, Philip Chun

PY - 2010

Y1 - 2010

N2 - Alzheimer's disease (AD) is the most common progressive dementia syndrome of the elderly. Because of prevalence, lack of mechanism-based treatments, care costs, and impact on individuals and families, AD is an extraordinarily challenging disease. It is characterized by dysfunction and death of specific populations of neurons, particularly those in neural systems involved in memory and cognition, and by intracellular and extracellular protein aggregates (tau and A. Α peptides) in neurofibrillary tangles (NFTs) and amyloid plaques, respectively. Genetic evidence indicates that the inheritance of mutations in several genes causes autosomal dominant familial AD (fAD) and the majority of mutations increase the levels of toxic A. Α amyloid peptide species in the brain. In this review, we describe the clinical features, diagnostic studies, the neuropathology, and the biochemistry of the disease with a particular focus on the amyloid precursor protein and Α- and Α-secretase enzyme activities which generate the A. Α peptide. Taking advantage of this new information, and the ability to manipulate genes, it is has been possible to produce transgenic models of the disease and to target genes encoding proteins critical in the disease pathways. In turn, this information has been used to develop experimental therapeutics, including strategies to reduce secretase activities and to clear the amyloid peptide from the brain. These discoveries offer genuine hope for the development of mechanism-based therapeutics for this illness.

AB - Alzheimer's disease (AD) is the most common progressive dementia syndrome of the elderly. Because of prevalence, lack of mechanism-based treatments, care costs, and impact on individuals and families, AD is an extraordinarily challenging disease. It is characterized by dysfunction and death of specific populations of neurons, particularly those in neural systems involved in memory and cognition, and by intracellular and extracellular protein aggregates (tau and A. Α peptides) in neurofibrillary tangles (NFTs) and amyloid plaques, respectively. Genetic evidence indicates that the inheritance of mutations in several genes causes autosomal dominant familial AD (fAD) and the majority of mutations increase the levels of toxic A. Α amyloid peptide species in the brain. In this review, we describe the clinical features, diagnostic studies, the neuropathology, and the biochemistry of the disease with a particular focus on the amyloid precursor protein and Α- and Α-secretase enzyme activities which generate the A. Α peptide. Taking advantage of this new information, and the ability to manipulate genes, it is has been possible to produce transgenic models of the disease and to target genes encoding proteins critical in the disease pathways. In turn, this information has been used to develop experimental therapeutics, including strategies to reduce secretase activities and to clear the amyloid peptide from the brain. These discoveries offer genuine hope for the development of mechanism-based therapeutics for this illness.

UR - http://www.scopus.com/inward/record.url?scp=84882834235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882834235&partnerID=8YFLogxK

U2 - 10.1016/B978-008045046-9.00539-8

DO - 10.1016/B978-008045046-9.00539-8

M3 - Chapter

AN - SCOPUS:84882834235

SN - 9780080450469

SP - 187

EP - 195

BT - Encyclopedia of Neuroscience

PB - Elsevier Ltd

ER -